McLennan Daniel, Ivy Dunbar, Morgan Gareth J
Division of Cardiology, Heart Institute, Children's Hospital Colorado, University of Colorado Denver, Aurora, Colorado.
Congenit Heart Dis. 2019 Sep;14(5):819-831. doi: 10.1111/chd.12816. Epub 2019 Jul 22.
To evaluate in domestic pigs the histopathological processes after implanting the Occlutech Atrial Flow Regulator (AFR).
Eleven pigs were chosen and had successful implantation of the AFR. Five pigs were sacrificed at 28 days, and 5 pigs at 90 days. One pig was sacrificed at day 3 after device embolization. Each pig had echocardiography performed at 3 weeks to check patency. Post mortem evaluation included Gross evaluation, radiographic evaluation, histology, and electron microscopy. Nine of the 10 devices implanted remained patent at time of autopsy with no thrombus and minimal inflammation. One device placed in the PFO closed by day 28 and the other embolized on day 3.
The Occlutech AFR has shown to be safe and easy to implant with good results [Krizanic et al. J Invasive Cardiol. 2010;22(4):182.]. This study has further shown that histologically the device does not cause any end organ damage, causes minimal inflammation, with almost no thrombus formation and can remain patent and secure in the atrial septum.
在家猪体内评估植入Occlutech心房血流调节器(AFR)后的组织病理学过程。
选取11头猪,成功植入AFR。5头猪在28天时处死,5头猪在90天时处死。1头猪在装置栓塞后第3天处死。每头猪在3周时进行超声心动图检查以检查通畅情况。尸检评估包括大体评估、影像学评估、组织学和电子显微镜检查。在尸检时,植入的10个装置中有9个保持通畅,无血栓形成且炎症轻微。1个放置在卵圆孔未闭处的装置在28天时闭合,另1个在第3天发生栓塞。
Occlutech AFR已证明安全且易于植入,效果良好[Krizanic等人。《侵入性心脏病学杂志》。2010年;22(4):182。]。本研究进一步表明,从组织学角度看,该装置不会引起任何终末器官损伤,炎症轻微,几乎无血栓形成,并且可在房间隔中保持通畅和稳固。